22 November 2021

European Urology Focus report on EUPROMS emphasises importance of such studies

The findings of Europa Uomo’s first innovative EUPROMS study have been published in the prestigious journal European Urology Focus. “This is the first time that the authentic prostate cancer patient voice has been heard in such detail and volume across Europe,” say the authors, who include Europa Uomo Board members and urology and epidemiology experts from Erasmus University Medical Center in the Netherlands.

With the follow-up EURPROMS 2.0 survey now underway, the report serves as a reminder of the significance of these studies, which provide a picture of the quality of life of the current prostate cancer population. The resulting data can inform physicians and patients on the true impact of prostate cancer treatment.

“Europa Uomo wanted to investigate what the real burden of prostate cancer treatment is, with the aim of informing future patients about the impact of treatment through self-reported PRO [patient-reported outcome] data of fellow patients collected outside a clinical trial setting,” says the newly-published report.

“The self-reported quality of life of patients in the EUPROMS survey can be of aid in informing fellow patients about what to expect after prosate cancer treatment in terms of quality of life, and hence has the potential to lower treatment decision regret.”

The first EUPROMS study found that prostate cancer progression leads to more insomnia, surgery is the treatment that leads to most urinary incontinence, and sexual function is affected most for men who undergo surgery and radiotherapy.

Now the EUPROMS 2.0 study is building on such findings, using a second survey to find the answers to vital questions such as:

  • Is the quality of life of men with prostate cancer better if early detection programmes are in use?
  • Is quality of life better if men are treated in multidisciplinary centres?
  • To what extent does quality of life decline in the later stages, when patients are receiving ADT and chemotherapy?

You can complete the EUPROMS 2.0 study questionnaire here.